卡瑞利珠单抗联合仑伐替尼或贝伐珠单抗治疗肝癌的疗效分析

Clinical efficacy of camrelizumab combined with lunvatinib or bevacizumab in the treatment of hepatocellular carcinoma

目的探讨卡瑞利珠单抗联合仑伐替尼或贝伐珠单抗治疗肝细胞癌(肝癌)的疗效差异。方法回顾性分析60例肝癌患者的资料,患者以不同治疗方法为A组(卡瑞利珠单抗联合仑伐替尼)和B组(卡瑞利珠单抗联合贝伐珠单抗)。比较2组近期治疗效果及血清肿瘤标志物(甲胎蛋白、癌胚抗原、神经元特异性烯醇化酶、细胞角蛋白19片段)、基质金属蛋白酶-9(MMP-9)及血管内皮生长因子(VEGF)水平,采用癌因性疲乏(CRF)评估量表评价2组治疗前的CRF程度,并比较2组治疗期间不良反应发生率、无进展生存情况和总生存情况。结果2组的近期治疗效果、不良反应发生率、无病生存情况和总生存情况比较差异均无统计学意义(P均>0.05)。2组治疗后的血清肿瘤标志物、MMP-9、VEGF水平和CRF评分均比治疗前低,且B组均比A组低(P均<0.05)。结论卡瑞利珠单抗联合仑伐替尼或贝伐珠单抗治疗肝癌患者的疗效未发现明显差异,但卡瑞利珠单抗联合贝伐珠单抗治疗可以使患者的血清肿瘤标志物及MMP-9及VEGF水平下降更明显,且可改善CRF。

Objective To evaluate the clinical efficacy of camrelizumab combined with lunvatinib or bevacizumab in the treatment of hepatocellular carcinoma(HCC).Methods Clinical data of 60 patients with HCC were retrospectively analyzed.All patients were divided into group A(camrelizumab combined with lunvatinib)and group B(camrelizumab combined with bevacizumab).Short-term clinical efficacy and the expression levels of serum tumor markers(alpha-fetoprotein,carcinoembryonic antigen,neuron-specific enolase,cytokeratin 19 fragment),matrix metalloproteinase-9(MMP-9)and vascular endothelial growth factor(VEGF)were compared between two groups.The degree of cancer-related fatigue(CRF)before treatment was compared between two groups by using CRF scale.The incidence of adverse reactions,progression-free survival(PFS)and overall survival(OS)during the treatment were analyzed between two groups.Results No significant differences were observed in the short-term clinical efficacy,incidence of adverse reactions,PFS and OS between two groups(all P>0.05).After treatment,the expression levels of serum tumor markers,MMP-9,VEGF and CRF scores in two group were significantly lower than those before treatment,and the values in group B were lower than those in group A(all P<0.05).Conclusions No significant difference is observed in the clinical efficacy between camrelizumab combined with lunvatinib or bevacizumab in the treatment of HCC patients.However,combined use of camrelizumab and bevacizumab can significantly lower the expression levels of serum tumor markers,MMP-9 and VEGF and mitigate CRF in HCC patients.